JAK1/3抑制在特应性皮炎和银屑病全层3D皮肤模型中维持表皮形态
研究用特应性皮炎(AD)样与银屑病样全层3D皮肤模型,预处理托法替布以抑制JAK1/3,评估角质形成细胞免疫与屏障形成。托法替布预处理维持了表皮形态,降低AD样模型中STAT3、STAT6磷酸化及银屑病样模型中STAT3磷酸化。AD样模型中丝聚蛋白表达完全维持,银屑病样模型中仅部分维持。
要点
- 托法替布预处理在AD样与银屑病样3D模型中维持表皮形态。
- AD样模型中丝聚蛋白表达完全维持,银屑病样模型中仅部分维持。
- JAK1/3抑制在AD样模型中的作用较银屑病样模型更明显。
核心结论
- JAK1/3抑制可逆转细胞因子诱导的AD样与银屑病样表皮形态改变,并在3D皮肤模型中增强角质形成细胞分化。
- 该效应在AD样模型中较银屑病样3D皮肤模型更为明显。
研究设计与样本
- 研究构建AD样与银屑病样全层3D皮肤等效物,并同时用托法替布预处理。
- AD样条件由重组人IL-4和IL-13刺激诱导,银屑病样条件由IL-17A、IL-22和肿瘤坏死因子α(TNFα)孵育诱导。
- 用Western blot分析评估信号转导及转录激活因子(STAT)1、STAT3和STAT6的活化,用微阵列分析和实时定量PCR进行基因表达分析。
主要发现
- 与假对照相比,托法替布预处理维持了表皮形态,并降低AD样培养条件的STAT3和STAT6磷酸化及银屑病样培养条件的STAT3磷酸化。
- AD样模型中丝聚蛋白表达完全维持,银屑病样条件下经托法替布预处理后仅部分维持。
- 托法替布上调DSC1、FLG和KRT1。
- 基因表达分析显示AD样条件下POSTN和IL24下调,银屑病样条件下IL20和IL1B下调。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Janus kinase (JAK) inhibition may be a promising new treatment modality for inflammatory (skin) diseases. However, little is known about direct effects of kinase inhibitors on keratinocyte differentiation and function as well as skin barrier formation. OBJECTIVE: Our aim was to address the direct impact of kinase inhibition of the JAK1/3 pathways by tofacitinib on keratinocyte immune function and barrier formation in atopic dermatitis (AD) and psoriasis. METHODS: 3D skin equivalents of both diseases were developed and concurrently pretreated with tofacitinib. To induce AD, 3D skin equivalents were stimulated with recombinant human IL-4 and IL-13. Psoriasis-like conditions were induced by incubation with IL-17A, IL-22 and tumour necrosis factor α (TNFα). The activation of signal transducer and activator of transcription (STAT)1, STAT3 and STAT6 was assessed by Western blot analysis. Microarray analysis and quantitative real-time PCR were used for gene expression analysis. RESULTS: Tofacitinib pretreatment preserved epidermal morphology and reduced STAT3 and STAT6 phosphorylation of AD-like and STAT3 phosphorylation of psoriasis-like culture conditions in 3D skin models compared to sham-controls. Filaggrin expression was fully maintained in the AD-like models, but only partially in psoriasis-like conditions after pretreatment with tofacitinib. In addition, tofacitinib upregulated DSC1, FLG and KRT1. Using gene expression analysis, downregulation of POSTN and IL24 was observed in AD-like conditions, whereas downregulation of IL20 and IL1B was observed in psoriasis-like conditions. CONCLUSION: JAK1/3 inhibition counteracted cytokine-induced AD- and psoriasis-like epidermal morphology and enhanced keratinocyte differentiation in 3D skin models. This effect was more pronounced in the AD-like models compared to the psoriasis-like 3D skin models.
引用
- Clarysse K, Pfaff CM, Marquardt Y, et al. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 30357932. doi:10.1111/jdv.15301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。